Cardiovascular Risk of Resistant Hypertension: Dependence on Treatment-Time Regimen of Blood Pressure–Lowering Medications
- 24 September 2012
- journal article
- research article
- Published by Informa UK Limited in Chronobiology International
- Vol. 30 (1-2), 340-352
- https://doi.org/10.3109/07420528.2012.701455
Abstract
In resistant hypertension, ingesting one or more blood pressure (BP)-lowering medications at bedtime is associated with significant reduction of sleep-time BP, a sensitive prognostic marker of cardiovascular disease (CVD) risk. This randomized trial investigated if bedtime therapy with at least one hypertension medication exerts better BP control and CVD risk reduction than conventional, morning-time therapy with all medications. We conducted a prospective, open-label, blinded-endpoint trial on 776 patients (387 men/389 women) with resistant hypertension, 61.6 ± 11.2 (mean ± SD) yrs of age. Patients were randomized to ingest all their prescribed hypertension medications upon awakening or ≥1 of them at bedtime. BP was measured by ambulatory monitoring for 48 h at baseline, and again annually or more frequently (quarterly) if treatment adjustment was required. After a median follow-up of 5.4 yrs (range, .5-8.5 yrs), participants ingesting ≥1 hypertension medications at bedtime showed a significantly lower hazard ratio (HR) of total CVD events (adjusted by age, sex, and diabetes) than those ingesting all medications upon awakening (.38 [95% CI: .27-.55]; number of events 102 vs. 41; p < .001). The difference between groups in the adjusted HR of major CVD events (a composite of CVD death, myocardial infarction, ischemic stroke, and hemorrhagic stroke) was also statistically significant (.35 [95% CI: .18-.68]; number of events 32 vs. 12; p = .002). At the last evaluation, patients treated with the bedtime versus awakening-time-treatment regimen showed significantly lower sleep-time systolic/diastolic BP mean values (121.6/65.4 vs. 113.0/61.1 mm Hg; p < .001) and higher prevalence of controlled ambulatory BP (61% vs. 46%; p < .001). The progressive decrease in the sleep-time systolic BP mean during follow-up was the most significant predictor of event-free survival (15% risk reduction per 5 mm Hg decreased asleep systolic BP mean). Among patients with resistant hypertension, ingestion of at least one hypertension medication at bedtime, compared with all medications upon waking, resulted in improved ambulatory BP control and fewer hard and soft CVD events.Keywords
This publication has 57 references indexed in Scilit:
- Automatic identification of activity–rest periods based on actigraphyMedical & Biological Engineering & Computing, 2012
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney DiseaseNew England Journal of Medicine, 2010
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patientsDiabetes & Metabolism, 2008
- Resistant Hypertension: Diagnosis, Evaluation, and TreatmentHypertension, 2008
- Impaired Diurnal Blood Pressure Variation and All-cause MortalityAmerican Journal of Hypertension, 2008
- Prognostic accuracy of day versus night ambulatory blood pressure: a cohort studyThe Lancet, 2007
- Predictors of All-Cause Mortality in Clinical Ambulatory MonitoringHypertension, 2007
- Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) TrialJAMA, 2003
- High prevalence of cardiac and extracardiac target organ damage in refractory hypertensionJournal Of Hypertension, 2001